Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 15Lung Neoplasms 5Neoplasms 4Sarcoma 3Sarcoma, Ewing 2Neuroendocrine Tumors 2Desmoplastic Small Round Cell Tumor 2Stomach Neoplasms 1SCLC, Extensive Stage 1Platinum-Resistant Lung Small Cell Carcinoma 1Ovarian Neoplasms 1Neutropenia 1Mesothelioma 1Leiomyosarcoma 1Glioblastoma 1Gastrointestinal Malignancies 1Gastro-enteropancreatic neuroendocrine tumor 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1Advanced Solid Tumor 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 2sacituzumab govitecan 1enzalutamide 1atezolizumab 1abiraterone 1Penfluridol 1PT-100 dipeptide 1PM 01183 1Nivolumab 1Ipilimumab 1Etoposide 1EC regimen 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × PM 01183 × 1 year × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡